RALLYBIO CORPORATION Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
RALLYBIO CORPORATION (RLYB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$17.44 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-05-09
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$17.44M.
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$93.91M.
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$12.49M.
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$118.38M, a 437.24% decline from fiscal 2021.
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $35.10M, a 70.94% decline from fiscal 2020.
- RALLYBIO CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $120.78M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$17.44M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$118.38M 10-K · filed 2023-03-06 | |||
| 2022-09-30 | -$123.62M 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | -$114.58M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$93.91M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $35.10M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $46.74M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$27.50M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$12.49M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $120.78M 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $128.50M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $134.15M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |